IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer
- PMID: 17914107
- DOI: 10.1677/ERC-06-0073
IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer
Abstract
The IGF axis has documented growth-promoting effects in various malignancies, but its role in epithelial ovarian cancer (EOC) has not been adequately examined. We studied the expression of the IGF axis genes in relation to outcome in EOC. Microarray expression profiles from 64 patients with advanced-stage EOC were used. Two multi-gene subsets were chosen, one upstream of the IGF receptor ('IGF family') and the other downstream of the IGF receptor ('IGF signaling pathway'), and analyzed in relation to survival. In addition, expression patterns of the two gene subsets were analyzed in relation to favorable and unfavorable prognosis categories identified in a previous study by whole-genome expression profiling. In a gene-by-gene analysis, IGF binding protein 4 and IGF-II receptor gene expression was inversely associated with survival. Using hierarchical clustering, the two multi-gene subsets separated the patient cohort into two groups with different median survival (IGF family: 33 vs 63 months, P=0.02 and IGF signaling pathway: 41 vs 63 months, P=0.05). Furthermore, the two multi-gene subsets were differentially expressed between the previously defined favorable and unfavorable prognosis tumors (Kolmogorov-Smirnov permutation: P=0.0005 and 0.003 for the IGF family and signaling pathway respectively), and individual genes (including IGF-I, IGF-I receptor, and several genes downstream of the receptor) were overexpressed in unfavorable prognosis tumors (permutation P<0.05). The expression patterns of several genes in the IGF axis are associated with survival in EOC, and expression changes of these genes may be underlying previously proposed microarray-derived clinical prognostic models. Future studies are needed to more precisely determine the diagnostic and potential therapeutic significance of these findings.
Similar articles
-
The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.Clin Cancer Res. 2006 Feb 15;12(4):1208-14. doi: 10.1158/1078-0432.CCR-05-1801. Clin Cancer Res. 2006. PMID: 16489075
-
[Expression and prognostic significance in epithelial ovarian cancer].Minerva Ginecol. 2002 Feb;54(1):15-24. Minerva Ginecol. 2002. PMID: 11828267 Italian.
-
Gene expression and prognostic significance in ovarian cancer.Minerva Ginecol. 2004 Dec;56(6):495-502. Minerva Ginecol. 2004. PMID: 15729202 Review.
-
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.Cancer Res. 2007 Nov 1;67(21):10117-22. doi: 10.1158/0008-5472.CAN-07-2544. Cancer Res. 2007. PMID: 17974952
-
Gene-expression profiling in epithelial ovarian cancer.Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Nat Clin Pract Oncol. 2008. PMID: 18648354 Review.
Cited by
-
Diabetes and ovarian cancer: risk factors, molecular mechanisms and impact on prognosis.Endocrine. 2024 Jan;83(1):1-9. doi: 10.1007/s12020-023-03477-6. Epub 2023 Aug 8. Endocrine. 2024. PMID: 37552417 Review.
-
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1. Clin Cancer Res. 2016. PMID: 26831715 Free PMC article. Clinical Trial.
-
Inhibiting IGF1R-mediated Survival Signaling in Head and Neck Cancer with the Peptidomimetic SSTNIGF1R.Cancer Res Commun. 2023 Jan 19;3(1):97-108. doi: 10.1158/2767-9764.CRC-22-0274. eCollection 2023 Jan. Cancer Res Commun. 2023. PMID: 36968227 Free PMC article.
-
IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination.FEBS Open Bio. 2011 Dec 27;2:1-5. doi: 10.1016/j.fob.2011.12.001. Print 2012. FEBS Open Bio. 2011. PMID: 23650573 Free PMC article.
-
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.Oncotarget. 2016 Aug 30;7(35):56826-56841. doi: 10.18632/oncotarget.10862. Oncotarget. 2016. PMID: 27472395 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical